Prashant Khandagale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prashant Khandagale has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Yves Pommier
National Cancer Institute 2 Bethesda, Md
35 shared publications - Alfredo Berruti
Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia at ASST Spedali Civili, Brescia, Italy
33 shared publications - Andrea Abate
Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
33 shared publications - Constanze Hantel
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH) , Zurich, 8091
33 shared publications - Craig J. Thomas
National Institutes of Health
33 shared publications - Fathi Elloumi
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
33 shared publications
Latest Publications
- Open Access
SLFN11 restrains alternative lengthening of telomeres
Alternative lengthening of telomeres (ALT) is a homologous recombination-dependent mechanism maintaining telomere length in approximately 10-15% of all cancers that are telomerase (TERT) negative. ALT is most prominent in osteosarcoma. Although many ALT cells feature loss of the ATRX/DAXX chromatin remodeling complex, ATRX/DAXX deficiency alone is insufficient to trigger ALT. Here, we provide evidence that Schlafen 11 (SLFN11) acts as a suppressor of the ALT pathway. TERT-negative osteosarcoma U2-OS (ALT) cells that normally lack SLFN11 expression show SLFN11 localization to telomeres upon doxycycline-induced SLFN11 expression. This re-expression suppresses ALT activity, as evidenced by reduced ALT-associated PML bodies (APBs), c-circles and telomere DNA synthesis along with decreased levels of Telomeric Repeat-containing RNA (TERRA). SLFN11 re-expression also attenuates the telomeric DNA damage response (DDR) and induces telomere destabilization in ALT cells. Furthermore, SLFN11 suppresses ALT induction in ATRX-depleted prostate carcinoma DU145 and EW8 cells. Collectively, our findings identify SLFN11 as a negative regulator of the ALT pathway. These findings suggest that lack of SLFN11 expression together with ATRX/DAXX inactivation contributes to ALT activation, and that SLFN11 reactivation may be considered to eliminate ALT-dependent cancer cells.
Open AccessSLFN11 restrains alternative lengthening of telomeres
Alternative lengthening of telomeres (ALT) is a homologous recombination-dependent mechanism maintaining telomere length in approximately 10-15% of all cancers that are telomerase (TERT) negative. ALT is most prominent in osteosarcoma. Although many ALT cells feature loss of the ATRX/DAXX chromatin remodeling complex, ATRX/DAXX deficiency alone is insufficient to trigger ALT. Here, we provide evidence that Schlafen 11 (SLFN11) acts as a suppressor of the ALT pathway. TERT-negative osteosarcoma U2-OS (ALT) cells that normally lack SLFN11 expression show SLFN11 localization to telomeres upon doxycycline-induced SLFN11 expression. This re-expression suppresses ALT activity, as evidenced by reduced ALT-associated PML bodies (APBs), c-circles and telomere DNA synthesis along with decreased levels of Telomeric Repeat-containing RNA (TERRA). SLFN11 re-expression also attenuates the telomeric DNA damage response (DDR) and induces telomere destabilization in ALT cells. Furthermore, SLFN11 suppresses ALT induction in ATRX-depleted prostate carcinoma DU145 and EW8 cells. Collectively, our findings identify SLFN11 as a negative regulator of the ALT pathway. These findings suggest that lack of SLFN11 expression together with ATRX/DAXX inactivation contributes to ALT activation, and that SLFN11 reactivation may be considered to eliminate ALT-dependent cancer cells.
- Open Access
- 30 July 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (8) , 116066
Topoisomerase IIIα controls alternative lengthening of telomeres
- 30 July 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (8) , 116066
Open AccessTopoisomerase IIIα controls alternative lengthening of telomeres
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 1 related to Figure 2
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 1 related to Figure 2
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 2 related to Figure 4
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 2 related to Figure 4
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Table 2, related to Figure 5 and 6.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Table 2, related to Figure 5 and 6.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 3 related to Figure 8
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 3 related to Figure 8
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
- Open Access
Topoisomerase 3α (TOP3A) Dependent Alternative Lengthening of Telomeres (ALT)
Alternative Lengthening of Telomeres (ALT) is a homologous recombination-dependent telomere elongation mechanism utilized by at least 10-15% of all cancers. Here we identified that the DNA topoisomerase, TOP3A is enriched at the telomeres of ALT cells but not at the telomeres of telomerase-positive (Tel) cancer cells. We demonstrate that TOP3A stabilizes the shelterin protein TERF2 in ALT cancer cell lines but not in Tel cells and that long non-coding telomere transcribed RNA (TERRA) enrichment at telomeres depends upon TOP3A. TOP3A also promotes the generation of single-stranded telomeric C-strand (ssTeloC) DNA, which is a recently discovered marker for ALT. Additionally, we found that inducing TOP3A-DNA-protein crosslinks in ALT cells suppresses TERRA enrichment as well as destabilizes TERF2. Taken together these observations uncover the unexplored functions of TOP3A at ALT telomeres and suggest the potential of developing an ALT-specific cancer therapeutic strategy targeting TOP3A.
Open AccessTopoisomerase 3α (TOP3A) Dependent Alternative Lengthening of Telomeres (ALT)
Alternative Lengthening of Telomeres (ALT) is a homologous recombination-dependent telomere elongation mechanism utilized by at least 10-15% of all cancers. Here we identified that the DNA topoisomerase, TOP3A is enriched at the telomeres of ALT cells but not at the telomeres of telomerase-positive (Tel) cancer cells. We demonstrate that TOP3A stabilizes the shelterin protein TERF2 in ALT cancer cell lines but not in Tel cells and that long non-coding telomere transcribed RNA (TERRA) enrichment at telomeres depends upon TOP3A. TOP3A also promotes the generation of single-stranded telomeric C-strand (ssTeloC) DNA, which is a recently discovered marker for ALT. Additionally, we found that inducing TOP3A-DNA-protein crosslinks in ALT cells suppresses TERRA enrichment as well as destabilizes TERF2. Taken together these observations uncover the unexplored functions of TOP3A at ALT telomeres and suggest the potential of developing an ALT-specific cancer therapeutic strategy targeting TOP3A.
- Open Access
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Figure 3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Comparison of gene expression of CU-ACC cell lines and original PDXs. A, Overall correlation between gene expression in the cancer cell lines evaluated at the NCI and CU and their corresponding PDXs. Areas shaded in gray highlight the grouping of corresponding ACC cell lines and PDXs. B, Examples of coherent genes. Univariate analysis scatterplot of ABCB1 (MDR1) transcriptional expression level vs. ABCG2 (BCRP) and CYP21A2 transcriptional expression level vs. CYP11B1 transcriptional expression level. C, Example of differentially expressed genes related to cellular proliferation for the CU-ACC1 and CU-ACC2 cell lines and corresponding PDXs.
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Comparison of gene expression of CU-ACC cell lines and original PDXs. A, Overall correlation between gene expression in the cancer cell lines evaluated at the NCI and CU and their corresponding PDXs. Areas shaded in gray highlight the grouping of corresponding ACC cell lines and PDXs. B, Examples of coherent genes. Univariate analysis scatterplot of ABCB1 (MDR1) transcriptional expression level vs. ABCG2 (BCRP) and CYP21A2 transcriptional expression level vs. CYP11B1 transcriptional expression level. C, Example of differentially expressed genes related to cellular proliferation for the CU-ACC1 and CU-ACC2 cell lines and corresponding PDXs.